CKD-702 Plus Irinotecan in Gastric Cancer

Phase 2

Recruiting

• Conditions: Gastric Cancer
• Interventions: Drug: CKD-702 in combination with irinotecan

• Registration Number: NCT05750290
• Lead Sponsor: National Cancer Center, Korea

Brief Summary

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-01
• Status Verified: 2023-02
• Study First Submitted: 2023-02-09
• Study First Submitted QC: 2023-02-20
• Last Update Submitted: 2023-02-20
• Study First Posted: 2023-03-01
• Last Update Posted: 2023-03-01
• Primary Completion: 2024-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Failed 2 or more lines of chemotherapy
• Tumor overexpressing either MET or EGFR
• Measurable lesion

Exclusion Criteria

• Prior treatment with anti-MET/EGFR bispecific antibody

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CKD-702 in combination with irinotecan	CKD-702 in combination with irinotecan	-

Primary Outcome Measures

Name	Time	Method
Best objective response rate	Through study completion, an average of 24 weeks	RECIST v1.1

Trial Locations

Locations (1)

National Cancer Center; 🇰🇷 Goyang, Gyeonggi, Korea, Republic of